Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma

Hidenari Hirata, Keishi Sugimachi, Hisateru Komatsu, Masami Ueda, Takaaki Masuda, Ryutaro Uchi, Shotaro Sakimura, Sho Nambara, Tomoko Saito, Yoshiaki Shinden, Tomohiro Iguchi, Hidetoshi Eguchi, Shuhei Ito, Kotaro Terashima, Katsumi Sakamoto, Masakazu Hirakawa, Hiroshi Honda, Koshi Mimori

研究成果: ジャーナルへの寄稿記事

38 引用 (Scopus)

抄録

Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.

元の言語英語
ページ(範囲)3265-3276
ページ数12
ジャーナルCancer Research
76
発行部数11
DOI
出版物ステータス出版済み - 6 1 2016

Fingerprint

Fructose-Bisphosphatase
Hepatocellular Carcinoma
Glucose
Neoplasms
Gluconeogenesis
Glycolysis
Down-Regulation
Cell Line
Methylation
Therapeutics
Biomarkers
Phenotype
Recurrence
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. / Hirata, Hidenari; Sugimachi, Keishi; Komatsu, Hisateru; Ueda, Masami; Masuda, Takaaki; Uchi, Ryutaro; Sakimura, Shotaro; Nambara, Sho; Saito, Tomoko; Shinden, Yoshiaki; Iguchi, Tomohiro; Eguchi, Hidetoshi; Ito, Shuhei; Terashima, Kotaro; Sakamoto, Katsumi; Hirakawa, Masakazu; Honda, Hiroshi; Mimori, Koshi.

:: Cancer Research, 巻 76, 番号 11, 01.06.2016, p. 3265-3276.

研究成果: ジャーナルへの寄稿記事

Hirata, H, Sugimachi, K, Komatsu, H, Ueda, M, Masuda, T, Uchi, R, Sakimura, S, Nambara, S, Saito, T, Shinden, Y, Iguchi, T, Eguchi, H, Ito, S, Terashima, K, Sakamoto, K, Hirakawa, M, Honda, H & Mimori, K 2016, 'Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma', Cancer Research, 巻. 76, 番号 11, pp. 3265-3276. https://doi.org/10.1158/0008-5472.CAN-15-2601
Hirata, Hidenari ; Sugimachi, Keishi ; Komatsu, Hisateru ; Ueda, Masami ; Masuda, Takaaki ; Uchi, Ryutaro ; Sakimura, Shotaro ; Nambara, Sho ; Saito, Tomoko ; Shinden, Yoshiaki ; Iguchi, Tomohiro ; Eguchi, Hidetoshi ; Ito, Shuhei ; Terashima, Kotaro ; Sakamoto, Katsumi ; Hirakawa, Masakazu ; Honda, Hiroshi ; Mimori, Koshi. / Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. :: Cancer Research. 2016 ; 巻 76, 番号 11. pp. 3265-3276.
@article{75de358046854c619efd5da004da7d9c,
title = "Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma",
abstract = "Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.",
author = "Hidenari Hirata and Keishi Sugimachi and Hisateru Komatsu and Masami Ueda and Takaaki Masuda and Ryutaro Uchi and Shotaro Sakimura and Sho Nambara and Tomoko Saito and Yoshiaki Shinden and Tomohiro Iguchi and Hidetoshi Eguchi and Shuhei Ito and Kotaro Terashima and Katsumi Sakamoto and Masakazu Hirakawa and Hiroshi Honda and Koshi Mimori",
year = "2016",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-15-2601",
language = "English",
volume = "76",
pages = "3265--3276",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma

AU - Hirata, Hidenari

AU - Sugimachi, Keishi

AU - Komatsu, Hisateru

AU - Ueda, Masami

AU - Masuda, Takaaki

AU - Uchi, Ryutaro

AU - Sakimura, Shotaro

AU - Nambara, Sho

AU - Saito, Tomoko

AU - Shinden, Yoshiaki

AU - Iguchi, Tomohiro

AU - Eguchi, Hidetoshi

AU - Ito, Shuhei

AU - Terashima, Kotaro

AU - Sakamoto, Katsumi

AU - Hirakawa, Masakazu

AU - Honda, Hiroshi

AU - Mimori, Koshi

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.

AB - Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84975038089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975038089&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2601

DO - 10.1158/0008-5472.CAN-15-2601

M3 - Article

C2 - 27197151

AN - SCOPUS:84975038089

VL - 76

SP - 3265

EP - 3276

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -